| Top 50 Most Viewed Posts Last Month |
|---|
|
Today This Week Last Week This Month Last Month
|
| 1. Rosner: Short Interest Report As of Sat, Aug 3, '13 (7794) |
2. biloxiblues: Leronlimab Phase 1b/2 Trial Dosing Flowchart (3529)  (11) |
| 3. MGK_2: I think you're spot on mfglola. I wrote (2036) (13) |
| 4. Riztheinvestor: https://www.dynotx.com/ Couldn’t this be our (1948) (27) |
| 5. MGK_2: I have a question on a (1946) (2) |
| 6. sherlock57: MGK2— You suggested the piece was gonna be (1817) (25) |
| 7. Mr3Putt: Wowza new branding for CytoDyn! (1695) (17) |
| 8. Cycl2R: I don’t believe it has been noted here that the (1424) (12) |
| 9. MJS719: Thank you brentie for the reminder of how (1405) (10) |
| 10. MGK_2: So, in the experiment, they took 4 monkeys (1399) (14) |
| 11. ohm20: Regarding posting my scientific posts from here (1211) (11) |
| 12. Chasing Stars: Getting started on Investors Hangout. Are you (1183) (14) |
| 13. MGK_2: ohm, as you know, most of us Greatly value your (1144) (6) |
| 14. KenChowder: I may not be reading the abstract right. Yes, (1130) (13) |
| 15. biloxiblues: We have a connection with the White House and (1046) (5) |
| 16. My69z: Huge from WH on PBM middlemen: The Order builds (1045) (11) |
| 17. brentie: We get a mention. (1010) (14) |
| 18. sean007: According to sourced information over 2.2 million (969) (5) |
| 19. MGK_2: Very concise, so I figure it might get some (965) (13) |
| 20. Ibam44: Hi all. I work in the film industry. I write (963) |
| 21. chazzledazzle: This is from 2016. Am I missing something new? (950) (1) |
| 22. testuser: A Agilent Technologies AA Alcoa Inc. AAN Aaron's (928) |
| 23. brentie: "Other changes from Makary include a shift away (877) (6) |
| 24. dfwl28: Excerpt: "Methods: By taking advantage of a newly (843) (12) |
| 25. sunray3: I agree. I posted this over on Reddit, It's what (842) (15) |
| 26. oMandarin: https://x.com/JimFergusonUK/status/19131254738752 (821) (13) |
| 27. sean007: In 2011, the FDA revoked Avastin's (Bevaziumab) (811) (5) |
| 28. sean007: Cytodyn: Join the Team...careers @ cytodyn.com * (810) (4) |
| 29. Harpitdown: Good news, bad news. The "good" news is that as (791) (8) |
| 30. ohm20: These would be the trial benchmarks LL would be (790) (23) |
| 31. misiu143: I am very surprised Europe approved this drug at (788) (12) |
| 32. sean007: Given what has been released publicly...any (779) (7) |
| 33. ohm20: would a Phase III that repeats the Phase II be (775) (13) |
| 34. sean007: Going back about five years ago, GSK (ViiV and (766) (7) |
| 35. nelsonsjavaheads: This morning on CNBC, Scott Gottlieb said the (760) (17) |
| 36. Katangolo: Holy crap buddy! That’s an amazing find thanks (754) (3) |
| 37. Riztheinvestor: Something’s up. My spidey senses has been going (748) (8) |
| 38. Jake13: $CBT Cabot Corp 55.72 Had 59,859 1 Month Highs. (745) |
| 39. TechGuru: SamaGong. In clinical trials ideally all the (720) (16) |
| 40. My69z: Did LL cure Acinetobacter baumannii during (718) (7) |
| 41. sean007: CCR5 has been in play for a very long time...it (716) (1) |
| 42. USS JOHNSTON: Regarding breast cancer, I see there are over 100 (709) (3) |
| 43. TechGuru: Not sure if this has been posted before, if so, (699) (10) |
| 44. Katangolo: Big stacks to small stacks if you don’t know (692) (3) |
| 45. KenChowder: Key Board Member Identity Revealed.... For those (686) (6) |
| 46. docj: I reposted it on Ihub for all the good it (678) (7) |
| 47. biloxiblues: This isn’t a rally cry. It’s a reality check. (677) (15) |
| 48. TechGuru: Following some discussion earlier on about the (673) (17) |
| 49. Katangolo: And surprise…BMGF are involved in funding new (672) (10) |
| 50. Cycl2R: “We’re removing Pharma members from the FDA (671) (3) |
